HCW Biologics Inc. 8-K

What Happened HCW Biologics Inc. (HCWB) filed an 8-K reporting results from its June 15, 2026 Annual Meeting of Stockholders. Stockholders re-elected Class II directors Lisa M. Giles and Rick S. Greene for three-year terms, ratified Crowe LLP as the company’s independent auditor for fiscal 2026, approved a certificate amendment to permit a reverse stock split (range 1-for-5 to 1-for-20) to be implemented within one year if needed to maintain Nasdaq listing, and approved two shareholder votes required under Nasdaq rules to allow issuance/exercise of warrants issued in connection with recent financings and a repricing of existing warrants.

Key Details

• Director elections: Lisa M. Giles — For 1,127,580; Withheld 230,984; Broker non-votes 1,189,957. Rick S. Greene — For 1,128,039; Withheld 230,525; Broker non-votes 1,189,957.
• Auditor ratification: Crowe LLP ratified — For 2,536,919; Against 1,748; Abstain 9,854.
• Reverse split approval: Amendment permitting reverse stock splits of 1:5 up to 1:20 — For 2,231,771; Against 258,125; Abstain 58,625.
• Warrant approvals (Nasdaq Rule 5635(d)): Approval to issue shares on exercise of up to 2,477,292 Common Warrants from the Feb. 17, 2026 follow-on offering — For 1,102,910; Against 233,136; Abstain 22,518; Broker non-votes 1,189,957. Approval to reprice and issue up to 3,020,410 Existing Warrants (exercise price reduced to $0.6055) — For 1,083,864; Against 251,605; Abstain 23,095; Broker non-votes 1,189,957.
• Warrant exercise price for the approved issuances/repricing: $0.6055 per share.

Why It Matters These votes affect corporate governance and potential share dilution. The reverse split authorization gives the company a tool to meet Nasdaq minimum listing requirements if needed. Shareholder approval of the warrant issuances and repricing clears a Nasdaq compliance step and allows up to 5,497,702 additional shares to be issued if all approved warrants are exercised (2,477,292 + 3,020,410), at $0.6055 per share, which could dilute existing shareholders. Ratifying the auditor and re-electing directors confirm continuity in the company’s leadership and financial oversight.